Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Orica
South San Francisco, California, United Statesoricpharma.com ↗
- Ownership
- Private
- Employees
- ~85
- Development stage
- Other
01
Overview
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by overcoming resistance in cancer. The company's name is an acronym for its mission: Overcoming Resistance In Cancer. ORIC leverages its proprietary resistance platform to develop small molecule therapies that target diverse mechanisms of resistance, including bypass signaling, lineage plasticity, and target mutations. Its lead programs include ORIC-114, a brain-penetrant inhibitor of EGFR and HER2, and ORIC-944, a potent and selective inhibitor of the PRC2 complex. Headquartered in South San Francisco, the company is led by a team of experienced oncology drug hunters and is publicly traded on the Nasdaq.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Orica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orica.